Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22423316 | 1.00 | NT5E (0.37) | NT5EPDPK1MTORALDH1A1CYP2D6 | |
| SCHEMBL12757246 | 1.00 | NT5E (0.37) | NT5EPDPK1MTORALDH1A1CYP2D6 | |
| SCHEMBL2779820 | 0.91 | PDPK1 (0.38) | NT5EPDPK1MTORPTPN1CDC25B | |
| SCHEMBL20854863 | 0.91 | PDPK1 (0.38) | NT5EPDPK1MTORPTPN1CDC25B | |
| SCHEMBL7554868 | 0.91 | PDPK1 (0.38) | NT5EPDPK1MTORPTPN1CDC25B | |
| SCHEMBL10031484 | 0.91 | PDPK1 (0.38) | NT5EPDPK1MTORPTPN1CDC25B | |
| SCHEMBL22181021 | 0.91 | PDPK1 (0.38) | NT5EPDPK1MTORPTPN1CDC25B | |
| SCHEMBL8597607 | 0.91 | PDPK1 (0.38) | NT5EPDPK1MTORPTPN1CDC25B | |
| SCHEMBL1973777 | 0.90 | NT5E (0.36) | NT5EPDPK1MTORPTPN1CDC25B | |
| SCHEMBL15975393 | 0.89 | FGF2 (0.35) | NT5EALDH1A1CYP2D6MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086767-A1 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES | INSTITUT PASTEUR | 2011-04-14 | — | — | US | disclosed |
| EP-2271752-A2 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES | Institut Pasteur (FR) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009112950-A2 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES | INSTITUT PASTEUR (FR) | 2009-09-17 | — | — | WO | disclosed |
| EP-2100965-A1 | Mutants of glycoside hydrolases and uses thereof for synthesizing complex oligosaccharides and disaccharide intermediates | Institut Pasteur (FR) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086767-A1 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES | ENGASE, GALE, MGAM | NT5E 725/4885PDPK1 4179/4885MTOR 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.